Real world study of regimen containing bevacizumab as first-line therapy in Chinese patients with advanced non-small cell lung cancer.

Puyuan XingYuxin MuYan WangXuezhi HaoYi-Xiang ZhuXingsheng HuHongyu WangPeng LiuLin LinZhijie WangJunling Li

Published in: Thoracic cancer (2018)

Our analysis confirmed that a first-line regimen containing bevacizumab showed superior clinical benefits over a non-bevacizumab regimen in Chinese patients with advanced NS-NSCLC in a real world setting.

Keyphrases

advanced non small cell lung cancer
metastatic colorectal cancer
epidermal growth factor receptor
small cell lung cancer
tyrosine kinase
dengue virus
smoking cessation
replacement therapy